NNNN Anbio Biotechnology Class A Ordinary Shares
Healthcare$32.52+7.50%ClosedMarket Cap: $1.43B
As of 2026-05-25
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
DE
Exchange
—
Beta
4.66
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
